Navigation Links
UT Southwestern receives continued NIH funding for Inner City Asthma Consortium
Date:11/22/2009

DALLAS Nov. 23, 2009 UT Southwestern Medical Center is among 10 institutions selected by the National Institutes of Health to share $56 million over five years as part of the Inner City Asthma Consortium (ICAC).

The ICAC, which receives funding through the NIH's National Institute of Allergy and Infectious Diseases, investigates novel treatments and causes of asthma in urban children.

Dr. Rebecca Gruchalla, chief of allergy and immunology at UT Southwestern, said continued funding of the consortium is imperative because morbidity and mortality continues to be highest in inner-city children and adolescents with asthma. Dr. Gruchalla has led the Dallas arm of the ICAC for seven years.

"The proposed studies undertaken through our continued role in the ICAC are novel, innovative and likely to help us truly make a difference in the lives of inner-city children suffering from this often debilitating disease," Dr. Gruchalla said.

Ongoing studies include a prospective, longitudinal evaluation of environmental factors that influence the development of the immune system and asthma, as well as clinical trials of possible treatment therapies.

Previous ICAC-funded research has found that:

  • A coordinated, guidelines-based approach to asthma management quickly controls asthma among inner-city adolescents.
  • Adding exhaled nitric oxide to guidelines-based care does not improve clinical outcomes.
  • Screening tests used to predict asthma activity in some patients may have little tracking success when applied to people with persistent disease who are adhering to their health care regimens.

With continued NIH funding, Dr. Michelle Gill, assistant professor of pediatrics at UT Southwestern, is leading key mechanistic studies that explore how anti-IgE therapy can decrease viral-induced seasonal asthma exacerbations. IgE antibodies are the fuel in the immune system that perpetuates asthmatic reactions and can make asthma worse in people who are sensitive to particular allergens.

"The goal of our mechanistic studies is to define how allergens interfere with immune responses to respiratory viruses. We will also investigate whether anti-IgE therapy improves these responses to seasonal viral infections in patients with asthma," Dr. Gill said.

The consortium is administered by the University of Wisconsin-Madison. In addition to UT Southwestern, research is being conducted at Boston University School of Medicine; Children's Memorial Hospital in Chicago; George Washington University School of Medicine and Health Sciences in Washington, D.C.; National Jewish Health in Denver; Johns Hopkins University School of Medicine; University of California, San Francisco; Columbia University College of Physicians and Surgeons in New York City; and the Henry Ford Hospital in Detroit.


'/>"/>

Contact: Erin Prather Stafford
erin.pratherstafford@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert  

Related medicine news :

1. Director of UT Southwestern center honored with first international neurology medal
2. UT Southwestern Responds to VA Announcement
3. UT Southwestern physicians bust myths about insulin
4. UT Southwestern researchers launch study into search-and-destroy antigen for deadly skin cancer
5. Dysport proves safe, effective anti-wrinkle treatment, UT Southwestern plastic surgeons find
6. Higher drug doses needed to defeat tuberculosis, UT Southwestern researchers report
7. UT Southwestern, UT Arlington to develop magnetic surgery tools
8. UT Southwestern researcher named HHMI Early Career Physician-Scientist
9. Former Gov. Bill Clements Makes Historic Gift to UT Southwestern With $100 Million Transformative Contribution
10. UT Southwesterns Olson wins prestigious French award for heart research
11. Participants in antidepressant drug trials are atypical patients, UT Southwestern researchers report
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
UT Southwestern receives continued NIH funding for Inner City Asthma Consortium
(Date:3/27/2017)... ... March 27, 2017 , ... Osteitis pubis may be commonplace ... injury, it occurs when the muscles around the pelvis become inflamed. Over time, ... lower torso, as well as accompanying tenderness and weakness. Without proper intervention, it ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... epigenetic research products enables researchers to pursue the recent RNA methylation “gold rush” ... . In light of the newfound characteristics of N6-methyladenosine, or m6A , ...
(Date:3/27/2017)... ... March 27, 2017 , ... Janet Schloz is still in shock after receiving a $2,500 ... had in a long time,” she said. , She thinks the coming week is going ... never thought I would have to help my students.” , The award will allow the ...
(Date:3/27/2017)... ... March 27, 2017 , ... Sodium ... methods are complicated and require expert user knowledge. In a live webinar on ... to the simplified, yet highly accurate, determination of sodium. , It has long ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... facility from 8:00am-10:00am on Monday, April 3rd to commemorate the two-year anniversary of ... opportunity for area-residents to celebrate two great years while also familiarizing themselves with ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... , March 27, 2017  Cryoport, Inc. (NASDAQ: CYRX, ... intends to offer shares of common stock in an ... on file with the Securities and Exchange Commission (the ... conditions, and there can be no assurance as to ... as to the actual size or terms of the ...
(Date:3/27/2017)... 2017 To mark the end of Save Your ... leader in digital imaging solutions, will showcase Canon eye care ... New York,s Jacob Javits Center from ... sponsored by the American Optometric Association, is observed annually in ... comprehensive eye exams. In recognition of this observance, Canon ...
(Date:3/27/2017)... March 27, 2017  Sophiris Bio Inc. (NASDAQ: ... a clinical late-stage biopharmaceutical company developing topsalysin (PRX302) ... today reported fourth quarter and full year 2016 ... Key Corporate Highlights: Advanced ... Cancer. During 2016, the Company reported successful results ...
Breaking Medicine Technology: